AGONISTAS DO RECEPTOR GLP-1 NO TRATAMENTO DA OBESIDADE: IMPACTO NA PERDA DE PESO, CONTROLE GLICÊMICO E DESFECHOS CARDIOMETABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE
Revista Científica Ipedss · 2026 · 06 (02)
DOI: 10.55703/27644006060208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Científica Ipedss, 2026. Verfasst von Danilo Gustavo Gonçalves Ferreira Romanelli und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Obesity is a chronic and multifactorial disease associated with the development of type 2 diabetes mellitus, cardiovascular disease, heart failure, chronic kidney disease, and impaired quality of life. Glucagon-like peptide-1 receptor agonists have demonstrated clinically relevant effects on body weight and metabolic control. This study aimed to evaluate the efficacy and safety of selective GLP-1 receptor agonists for the treatment of overweight and obesity, considering their effects on weight loss, glycemic control, and cardiometabolic outcomes. A systematic review and meta-analysis of randomized clinical trials was conducted in accordance with the PRISMA 2020 recommendations. Forty publications, corresponding to 39 independent clinical cohorts, were included and evaluated semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, albiglutide, and efpeglenatide. Risk of bias was assessed using the Cochrane RoB 2 tool, and random-effects models were used for the quantitative syntheses. The analysis of trials evaluating subcutaneous semaglutide 2.4 mg in adults with obesity and without diabetes showed a pooled mean difference of −11.75 percentage points in body weight change compared with placebo, with a 95% confidence interval from −14.83 to −8.67. Weight loss was less pronounced among participants with type 2 diabetes mellitus, although clinically relevant reductions in glycated hemoglobin were observed. In cardiovascular outcome trials involving individuals with type 2 diabetes, GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events by approximately 14%, with a pooled hazard ratio of 0.86 and a 95% confidence interval from 0.79 to 0.94. Gastrointestinal adverse events were the most frequently reported reactions and contributed to treatment discontinuation. Selective GLP-1 receptor agonists were effective in reducing body weight and improving glycemic control and may also reduce cardiovascular events in high-risk populations. However, treatment effects varied across molecules, doses, and populations, supporting individualized treatment selection and long-term clinical monitoring. Keywords: obesity; glucagon-like peptide-1 receptor agonists; weight loss; cardiovascular diseases.
Zitieren
APA
Romanelli, D. G. G. F., & Romanelli, A. C. F. S. (2026). AGONISTAS DO RECEPTOR GLP-1 NO TRATAMENTO DA OBESIDADE: IMPACTO NA PERDA DE PESO, CONTROLE GLICÊMICO E DESFECHOS CARDIOMETABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE. Revista Científica Ipedss, 06(02). https://doi.org/10.55703/27644006060208
Vancouver
Romanelli DGGF, Romanelli ACFS. AGONISTAS DO RECEPTOR GLP-1 NO TRATAMENTO DA OBESIDADE: IMPACTO NA PERDA DE PESO, CONTROLE GLICÊMICO E DESFECHOS CARDIOMETABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE. Revista Científica Ipedss. 2026;06(02). doi:10.55703/27644006060208
BibTeX
@article{Romanelli2026,
author = {Romanelli, Danilo Gustavo Gonçalves Ferreira and Romanelli, Ana Cristina Faria Silva},
title = {AGONISTAS DO RECEPTOR GLP-1 NO TRATAMENTO DA OBESIDADE: IMPACTO NA PERDA DE PESO, CONTROLE GLICÊMICO E DESFECHOS CARDIOMETABÓLICOS – REVISÃO SISTEMÁTICA E METANÁLISE},
journal = {Revista Científica Ipedss},
year = {2026},
volume = {06},
number = {02},
doi = {10.55703/27644006060208}
}
EUVIMED